Literature DB >> 35181812

Systematic Review and Meta-Analysis of Prognostic Factors for Early Recurrence in Intrahepatic Cholangiocarcinoma After Curative-Intent Resection.

Woo Jin Choi1,2, Phil J Williams1, Marco P A W Claasen2,3, Tommy Ivanics2,4,5, Marina Englesakis6, Steven Gallinger1,2, Bettina Hansen7, Gonzalo Sapisochin8,9.   

Abstract

BACKGROUND: Recurrence rates of intrahepatic cholangiocarcinoma (iCCA) after curative hepatectomy are as high as 50% to 70%, and about half of these recurrences occur within 2 years. This systematic review aims to define prognostic factors (PFs) for early recurrence (ER, within 24 months) and 24-month disease-free survival (DFS) after curative-intent iCCA resections.
METHODS: Systematic searching was performed from database inception to 14 January 2021. Duplicate independent review and data extraction were performed. Data on 13 predefined PFs were collected. Meta-analysis was performed on PFs for ER and summarized using forest plots. The Quality in Prognostic Factor Studies tool was used for risk-of-bias assessment.
RESULTS: The study enrolled 10 studies comprising 4158 patients during an accrual period ranging from 1990 to 2016. In the risk-of-bias assessment of patients who experienced ER after curative-intent iCCA resection, six studies were rated as low risk and four as moderate risk (49.6%; 95% confidence interval [CI], 49.2-50.0). Nine studies were pooled for meta-analysis. Of the postoperative PFs, multiple tumors, microvascular invasion, macrovascular invasion, lymph node metastasis, and R1 resection were associated with an increased hazard for ER or a reduced 24-month DFS, and the opposite was observed for receipt of adjuvant chemo/radiation therapy. Of the preoperative factors, cirrhosis, sex, HBV status were not associated with ER or 24-month DFS.
CONCLUSION: The findings from this systematic review could allow for improved surveillance, prognostication, and treatment decision-making for patients with resectable iCCAs. Further well-designed prospective studies are needed to explore prognostic factors for iCCA ER with a focus on preoperative variables.
© 2022. Society of Surgical Oncology.

Entities:  

Year:  2022        PMID: 35181812     DOI: 10.1245/s10434-022-11463-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  32 in total

1.  Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma.

Authors:  John Bridgewater; Peter R Galle; Shahid A Khan; Josep M Llovet; Joong-Won Park; Tushar Patel; Timothy M Pawlik; Gregory J Gores
Journal:  J Hepatol       Date:  2014-03-27       Impact factor: 25.083

2.  Outcomes for Patients with Recurrent Intrahepatic Cholangiocarcinoma After Surgery.

Authors:  Hyeong Min Park; Sung Pil Yun; Eung Chang Lee; Seung Duk Lee; Sung-Sik Han; Seoung Hoon Kim; Sang-Jae Park
Journal:  Ann Surg Oncol       Date:  2016-08-31       Impact factor: 5.344

Review 3.  Clinical diagnosis and staging of cholangiocarcinoma.

Authors:  Boris Blechacz; Mina Komuta; Tania Roskams; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-08-02       Impact factor: 46.802

4.  Increased incidence but improved median overall survival for biliary tract cancers diagnosed in Ontario from 1994 through 2012: A population-based study.

Authors:  Jennifer A Flemming; Jina Zhang-Salomons; Sulaiman Nanji; Christopher M Booth
Journal:  Cancer       Date:  2016-05-16       Impact factor: 6.860

5.  Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?

Authors:  Yasser H Shaib; Jessica A Davila; Kathryn McGlynn; Hashem B El-Serag
Journal:  J Hepatol       Date:  2004-03       Impact factor: 25.083

6.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

7.  Very Early Recurrence After Liver Resection for Intrahepatic Cholangiocarcinoma: Considering Alternative Treatment Approaches.

Authors:  Diamantis I Tsilimigras; Kota Sahara; Lu Wu; Dimitrios Moris; Fabio Bagante; Alfredo Guglielmi; Luca Aldrighetti; Matthew Weiss; Todd W Bauer; Sorin Alexandrescu; George A Poultsides; Shishir K Maithel; Hugo P Marques; Guillaume Martel; Carlo Pulitano; Feng Shen; Olivier Soubrane; B Groot Koerkamp; Amika Moro; Kazunari Sasaki; Federico Aucejo; Xu-Feng Zhang; Ryusei Matsuyama; Itaru Endo; Timothy M Pawlik
Journal:  JAMA Surg       Date:  2020-09-01       Impact factor: 14.766

8.  Systemic inflammation score predicts survival in patients with intrahepatic cholangiocarcinoma undergoing curative resection.

Authors:  Yong Zhang; Shi-Ming Shi; Hua Yang; Liu-Xiao Yang; Zheng Wang; Xue-Dong Li; Dan Yin; Ying-Hong Shi; Ya Cao; Zhi Dai; Jian Zhou; Qing Chen
Journal:  J Cancer       Date:  2019-01-01       Impact factor: 4.207

9.  Moving the Needle Forward With Locoregional Treatment in Unresectable Cholangiocarcinoma-The Jury Is Still Out.

Authors:  Aaron J Scott; Rachna T Shroff
Journal:  JAMA Oncol       Date:  2020-01-01       Impact factor: 31.777

10.  Specific risk factors contributing to early and late recurrences of intrahepatic cholangiocarcinoma after curative resection.

Authors:  Changzheng Wang; Shujie Pang; Hui Si-Ma; Ning Yang; Haibin Zhang; Yong Fu; Guangshun Yang
Journal:  World J Surg Oncol       Date:  2019-01-03       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.